| Literature DB >> 24703698 |
Woo-Jin Song1, Prosenjit Mondal1, Andrew Wolfe2, Laura C Alonso3, Rachel Stamateris3, Benny W T Ong1, Owen C Lim1, Kil S Yang1, Sally Radovick4, Horacio J Novaira4, Emily A Farber5, Charles R Farber5, Stephen D Turner6, Mehboob A Hussain7.
Abstract
Early in the pathogenesis of type 2 diabetes mellitus (T2DM), dysregulated glucagon secretion from pancreatic α cells occurs prior to impaired glucose-stimulated insulin secretion (GSIS) from β cells. However, whether hyperglucagonemia is causally linked to β cell dysfunction remains unclear. Here we show that glucagon stimulates via cAMP-PKA-CREB signaling hepatic production of the neuropeptide kisspeptin1, which acts on β cells to suppress GSIS. Synthetic kisspeptin suppresses GSIS in vivo in mice and from isolated islets in a kisspeptin1 receptor-dependent manner. Kisspeptin1 is increased in livers and in serum from humans with T2DM and from mouse models of diabetes mellitus. Importantly, liver Kiss1 knockdown in hyperglucagonemic, glucose-intolerant, high-fat-diet fed, and Lepr(db/db) mice augments GSIS and improves glucose tolerance. These observations indicate a hormonal circuit between the liver and the endocrine pancreas in glycemia regulation and suggest in T2DM a sequential link between hyperglucagonemia via hepatic kisspeptin1 to impaired insulin secretion.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24703698 PMCID: PMC4058888 DOI: 10.1016/j.cmet.2014.03.005
Source DB: PubMed Journal: Cell Metab ISSN: 1550-4131 Impact factor: 27.287